Compare AHCO & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | SDGR |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | AHCO | SDGR |
|---|---|---|
| Price | $10.84 | $15.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $13.50 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,244,857,000.00 | $255,869,000.00 |
| Revenue This Year | $9.00 | $0.76 |
| Revenue Next Year | $6.93 | $4.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $8.51 | $10.95 |
| 52 Week High | $13.43 | $23.02 |
| Indicator | AHCO | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 44.62 |
| Support Level | $10.80 | $11.27 |
| Resistance Level | $12.87 | $16.47 |
| Average True Range (ATR) | 0.40 | 0.69 |
| MACD | 0.05 | -0.24 |
| Stochastic Oscillator | 55.61 | 17.60 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.